Financings in Brief: LifeCell
This article was originally published in The Gray Sheet
Executive Summary
LifeCell: Tissue repair company raises approximately $16 mil. from a Dec. 1 secondary offering of 4.0 mil. shares at $4.50 per share. The Woodlands, Texas-based firm's initial plans had also included the sale of 500,000 shares by selling shareholders ("The Gray Sheet" Oct. 20, p. 18). Proceeds are tabbed for further development, sales and marketing of its AlloDerm acellular dermal graft product, as well as for working capital and general corporate purposes. Underwriters Vector Securities International and Gruntal & Co. hold an overallotment option for 600,000 shares being offered by selling shareholders...
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.